ScripThe uncertainty created by potential tariffs and US healthcare strategies has seen some senior pharma figures express concern about the impact on M&A but GSK CEO Emma Walmsley is confident that de
In VivoStrong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ah
ScripWith drug pricing pressure building under President Donald Trump, Novartis CEO Vas Narasimhan used the company’s first-quarter sales and earnings call on 29 April to underscore the company’s support t
ScripAstraZeneca has made “a very strong start in 2025” and is in “an unprecedented catalyst rich period,” according to CEO Pascal Soriot but his media call to discuss the firm’s first-quarter results was,